Heparin-induced	heparin-induced	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
thrombosis	thrombosis	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
hemorrhage	hemorrhage	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Sixty-two	sixty-two	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
heparin-induced	heparin-induced	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
are	are	O	O	O	O
reported	reported	O	O	O	O
.	.	O	O	O	O

Clinical	clinical	O	O	O	O
manifestations	manifestations	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
disorder	disorder	O	O	O	O
include	include	O	O	O	O
hemorrhage	hemorrhage	O	DISEASE	OTHERS	I
or	or	O	O	O	O
,	,	O	O	O	O
more	more	O	O	O	O
frequently	frequently	O	O	O	O
,	,	O	O	O	O
thromboembolic	thromboembolic	O	DISEASE	OTHERS	I
events	events	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
receiving	receiving	O	O	O	O
heparin	heparin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Laboratory	laboratory	O	O	O	O
testing	testing	O	O	O	O
has	has	O	O	O	O
revealed	revealed	O	O	O	O
a	a	O	O	OTHERS	I
falling	falling	O	O	OTHERS	I
platelet	platelet	O	O	OTHERS	I
count	count	O	O	OTHERS	I
,	,	O	O	O	O
increased	increased	O	O	O	O
resistance	resistance	O	O	O	O
to	to	O	O	O	O
heparin	heparin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
aggregation	aggregation	O	O	O	O
of	of	O	O	O	O
platelets	platelets	O	O	O	O
by	by	O	O	O	O
the	the	O	O	O	O
patient	patient	O	O	O	O
's	's	O	O	O	O
plasma	plasma	O	O	O	O
when	when	O	O	O	O
heparin	heparin	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
added	added	O	O	O	O
.	.	O	O	O	O

Immunologic	immunologic	O	O	O	O
testing	testing	O	O	O	O
has	has	O	O	O	O
demonstrated	demonstrated	O	O	O	O
the	the	O	O	O	O
presence	presence	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
heparin-dependent	heparin-dependent	O	O	O	O
platelet	platelet	O	O	O	O
membrane	membrane	O	O	O	O
antibody	antibody	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
20	20	O	O	O	O
deaths	deaths	O	DISEASE	OTHERS	I
,	,	O	O	O	O
52	52	O	O	O	O
hemorrhagic	hemorrhagic	O	DISEASE	OTHERS	I
and	and	O	O	O	O
thromboembolic	thromboembolic	O	DISEASE	OTHERS	I
complications	complications	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
21	21	O	O	O	O
surgical	surgical	O	O	O	O
procedures	procedures	O	O	O	O
to	to	O	O	O	O
manage	manage	O	O	O	O
the	the	O	O	O	O
complications	complications	O	O	O	O
confirm	confirm	O	O	O	O
the	the	O	O	O	O
seriousness	seriousness	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
disorder	disorder	O	O	O	O
.	.	O	O	O	O

Specific	specific	O	O	O	O
risk	risk	O	O	O	O
factors	factors	O	O	O	O
have	have	O	O	O	O
not	not	O	O	O	O
been	been	O	O	O	O
identified	identified	O	O	O	O
;	;	O	O	O	O
therefore	therefore	O	O	O	O
,	,	O	O	O	O
all	all	O	O	O	O
patients	patients	O	O	O	O
receiving	receiving	O	O	O	O
heparin	heparin	CHEMICALS	O	OTHERS	I
should	should	O	O	O	O
be	be	O	O	O	O
monitored	monitored	O	O	O	O
.	.	O	O	O	O

If	if	O	O	O	O
the	the	O	O	O	O
platelet	platelet	O	O	O	O
count	count	O	O	O	O
falls	falls	O	O	O	O
to	to	O	O	O	O
less	less	O	O	O	O
than	than	O	O	O	O
100,000/mm3	100,000/mm3	O	O	O	O
,	,	O	O	O	O
while	while	O	O	O	O
the	the	O	O	O	O
patient	patient	O	O	O	O
is	is	O	O	O	O
receiving	receiving	O	O	O	O
heparin	heparin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
platelet	platelet	O	DISEASE	OTHERS	I
aggregation	aggregation	O	DISEASE	OTHERS	I
testing	testing	O	O	O	O
,	,	O	O	O	O
using	using	O	O	O	O
the	the	O	O	O	O
patient	patient	O	O	O	O
's	's	O	O	O	O
plasma	plasma	O	O	O	O
,	,	O	O	O	O
is	is	O	O	O	O
indicated	indicated	O	O	O	O
.	.	O	O	O	O

Management	management	O	O	O	O
consists	consists	O	O	O	O
of	of	O	O	O	O
cessation	cessation	O	O	O	O
of	of	O	O	O	O
heparin	heparin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
platelet	platelet	O	O	O	O
anti-aggregating	anti-aggregating	O	O	O	O
agents	agents	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
alternate	alternate	O	O	O	O
forms	forms	O	O	O	O
of	of	O	O	O	O
anticoagulation	anticoagulation	O	O	O	O
when	when	O	O	O	O
indicated	indicated	O	O	O	O
.	.	O	O	O	O

